Since the introduction of cisplatin either singly or in combination with other agents in the treatment of the common epithelial ovarian cancers some improvement was seen mainly in terms of higher complete response rates and possibly longer survival compared with non-cisplatin chemotherapy (Neijt et al., 1984; Edwards et al., 1983) . On the other hand, despite great efforts, no progress has been made in the past years towards further increases in CR rates or survival and there is an apparent plateau in the therapeutic results for advanced disease.
The present study was conducted to evaluate the antitumour activity and toxicity of the cisplatin-etoposide combination. We incorporated etoposide in a first line combination because it has not been evaluated yet as a first line treatment in ovarian cancer although studies of etoposide either singly or in combination as second or third line treatment have been somewhat encouraging with 7-29% partial remissions and some 10% complete remissions (Junji, 1982; Dittrich et al., 1986; Kuhnle et al., 1987; De Lena et al., 1986) . It also seemed possible that the synergistic effects of these drugs in other forms of cancer could prove advantageous in ovarian cancer patients (Hainsworth et al., 1985; Einhorn, 1986 (Table II ). In the remaining 11 patients therapy was discontinued after two courses because of progression (nine patients) and after three courses because of absence of signs of objective response (two patients) according to the protocol. These patients were offered a variety of chemotherapy regimes that included systemic or intraperitoneal chemotherapy.
Of the CRs one was seen in a patient with 3 cm residual disease and three in patients with > 1O cm.
Patients with liver and lung involvement all failed to respond to chemotherapy. No differences in response were found with regard to histological subtype, grade and age.
Toxic effects observed during this trial are summarized in Table III . There were no toxicity related deaths. Toxicity consisted mainly of myelosuppression, nausea/vomiting and alopecia. Grade 1 and 2 nephrotoxicity occurred in seven patients but it was transient and did not result in treatment delays.
However, one patient developed irreversible renal damage after the sixth course. Five patients required blood and one patient required a platelet transfusion. Febrile episodes associated with neutropenia occurred in three patients and were successfully treated with broad spectrum antibiotics. Of the total of 114 administered courses, nine (8%) were delayed for a median of 8.2 days because of myelosuppression. All seventeen patients receiving three (two patients with stable disease) or six aAll with positive cytology.
(15 patients with clinical response) reached the predicted maximal escalation dose of 120 mg m-' for both drugs. Five patients were removed from the study because of toxicity; one with debilitating neurotoxocity after the first cycle and four with acute vasomotor reactions on first contact with etoposide. This unexpected side-effect consisted of hypertension, tachycardia, sweating and discomfort appearing in less than a minute from the start of the drug infusion and lasting for 20-30 min. Corticosteroids were administered in all four cases. Readministration was not attempted because of the patient's refusal. (Athanassiou et al., 1988) . All five withdrawn patients had stage III disease, median age 61 and PS 1. One of them had no residual disease after the initial operation, three had 2-5 cm and one 5-10 cm residuals. In particular there was no liver or lung involvement, no history of past or concurrent medical illness and no history of allergy.
Second look operation was carried out in eight complete or good partial responders after six courses of chemotherapy (Table IV) . Pathological CR was documented in one (25%) of the four patients with clinical CR. This patient had > 10 cm residual disease on starting chemotherapy. Complete excision of disease found at second look was possible in three (43%) of seven pathological partial responders.
At the time of analysis (4 September 1988) 13/26 (50%) patients are alive and 13/26 (50%) have died (Figure 1 ). Of the 13 survivors, seven are alive and off treatment with no evidence 
Discussion
These response rates are lower than those generally reported with other cisplatin-based combinations (Neijt et al., 1987; Thigpen & Blessing, 1985) . One could argue that this could be a result of the poor prognostic features of this group of patients. However, even in this relatively small group of patients we feel the results suggest that etoposide has probably not added to cisplatin chemotherapy and should not be pursued as a front line treatment for advanced ovarian cancer.
Results of second look laparotomy were similar to those reported with other combinations (Ho et al., 1987; Copeland & Gershenson, 1986) . Toxicity in general was significant. Four (13%) patients were removed from the study because of etoposide acute vasomotor reactions; and one (3%) because of severe neurotoxicity. Life threatening thrombocytopenia occurred in one (3%) patient and certainly the quality of life was adversely affected in at least three (10%) patients with postural hypotension. The mechanism of this symptom could well be cisplatin induced autonomic neuropathy (Rosenfeld & Broder, 1984) . No comments are possible on survival because longer follow-up is needed. In our opinion, the cisplatin-etoposide combination was only moderately effective and considerably toxic to this treated group compared with other cisplatincontaining combinations.
